| Name | Title | Contact Details |
|---|
NavigatorMD, Inc. was founded in 2005 to address the rising demand for an integrated data analysis and health plan management solution. As an insurance broker, Ernest Youngblood, founder of NavigatorMD, watched the progressive increase in health care costs and identified the opportunity for organizations to save money while improving the overall wellness of a plan population. Youngblood led the organization of a multi-disciplinary team of healthcare professionals, ranging from physicians and pharmacologists to benefit consultants and C-Suite executives to develop its first product, Design180®. The intended purpose of this advisory team was to establish an understanding of the problems and hurdles that faced the business community in managing and understanding their health claims spend. This unique insight and knowledge was the basis of its technically sound, business-oriented approach to claims analysis and comprehensive health plan management. NavigatorMD launched its first product in 2008 with the mission of lowering health care costs and adding value to health plans by focusing on manageable costs and utilizing the power of data. Influenced by the concept of value-based insurance design, our health claims data analytics software was created under the advisory of various professionals, including former VP of Strategic H.R. Initiatives at Pitney Bowes, David Hom, who served as an early member of the NavigatorMD's Board of Directors. Early success and escalating interest in the product resulted in the formation of an advisory board comprising several influential experts in the field of Value-Based Insurance Design (VBID). In addition, NavigatorMD received support and referrals from two of the largest pharmaceutical companies in the U.S. that were responsible for funding the development of the Center for Value Based Health Management, among other value-based health care initiatives. NavigatorMD, the first step toward proactive health plan management.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Mount Saint Mary's Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Mount Saint Mary's Hospital is based in Lewiston, NY. You can find more information on Mount Saint Mary's Hospital at www.msmh.org
St. Francis Health Center is a Topeka, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Saint Ann Retirement Center is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.